Long-term trial of protection provided by adenovirus-vectored vaccine expressing the PPRV H protein

• Published in: npj vaccines Vol. 9; no. 1; p. 98
• Main Authors: Darpel, Karin E., Corla, Amanda, Stedman, Anna, Bellamy, Fiona, Flannery, John, Rajko-Nenow, Paulina, Powers, Claire, Wilson, Steve, Charleston, Bryan, Baron, Michael D., Batten, Carrie
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 03.06.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 631/250/254; 631/250/590; Adenoviruses; Animals; Biomedical and Life Sciences; Biomedicine; Immunization; Infectious Diseases; Medical Microbiology; Public Health; Vaccine; Vaccines; Virology
• ISSN: 2059-0105
• DOI: 10.1038/s41541-024-00892-2

A recombinant, replication-defective, adenovirus-vectored vaccine expressing the H surface glycoprotein of peste des petits ruminants virus (PPRV) has previously been shown to protect goats from challenge with wild-type PPRV at up to 4 months post vaccination. Here, we present the results of a longer-term trial of the protection provided by such a vaccine, challenging animals at 6, 9, 12 and 15 months post vaccination. Vaccinated animals developed high levels of anti-PPRV H protein antibodies, which were virus-neutralising, and the level of these antibodies was maintained for the duration of the trial. The vaccinated animals were largely protected against overt clinical disease from the challenge virus. Although viral genome was intermittently detected in blood samples, nasal and/or ocular swabs of vaccinated goats post challenge, viral RNA levels were significantly lower compared to unvaccinated control animals and vaccinated goats did not appear to excrete live virus. This protection, like the antibody response, was maintained at the same level for at least 15 months after vaccination. In addition, we showed that animals that have been vaccinated with the adenovirus-based vaccine can be revaccinated with the same vaccine after 12 months and showed an increased anti-PPRV antibody response after this boost vaccination. Such vaccines, which provide a DIVA capability, would therefore be suitable for use when the current live attenuated PPRV vaccines are withdrawn at the end of the ongoing global PPR eradication campaign.